Skip to content

Validation of the Two-minute Walk Test and the Ten-meter Walk Test in Individuals With Cancer

Comparison of the 2MWT, the 10MeWT and the 6MWT in Individuals With Cancer, a Validation Observational Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04750148
Acronym
2MWTOnco
Enrollment
56
Registered
2021-02-11
Start date
2021-02-15
Completion date
2021-03-31
Last updated
2023-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

6-minute walking test, 2-minute walking test, 10-meter walk test

Brief summary

The aim of this study is to assess the feasibility and the validity of the 2-minute walk test (2MWT) and the 10-meter walk test (10MeWT) compared to the 6-minute walk test (6MWT) for subjects with onco-hematological disease.

Detailed description

Cancer and its treatments have an impact on the body as a whole. The analysis of the subject's physical capacity is essential to know the basic level of the subject pre-treatment, to evaluate progress following rehabilitation, to set goals to prevent decline in physical capacity or to evaluate changes in physical capacity at different stages of survival. The 6-minute walk test (6MWT) is frequently used in the clinic to assess the physical capacity of the subject in oncology. A variant of the 6MWT exists and has been little studied in an oncological context: the 2-minute walk test (2MWT). The 2MWT is performed in the same way as the 6MWT: the same instructions and the same test procedure. It offers the advantage of being less tiring for the test subjects and saves clinicians time. The 2MWT has been validated in the past for people with COPD or after cardiac surgery. To our knowledge, it has not been validated for cancer patients. The 10-meter walk test (10MeWT) is frequently used in practice to assess patients' functional capacity. It would be another way to assess the walking ability with a short test. However, the relationship between the 2MWT, 6MWT and 10MeWT in an oncological context remain unclear.

Interventions

DIAGNOSTIC_TEST6-minute walking test

The subject walks as far as possible for 6 minutes along a 30m long corridor.

DIAGNOSTIC_TEST2-minute walking test

The subject walks as far as possible for 2 minutes along a 30m long corridor.

DIAGNOSTIC_TEST10-meter walk test

The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).

DIAGNOSTIC_TESTOne leg stance test

The time held in unipodal equilibrium is measured by the examiner.

Sponsors

Aline Reinmann
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have an onco-hematologic disease * Have medical authorization from the patient's oncologist authorizing gait tests * Participate in the HUG rehabilitation program * Be able to give consent by signature * To be of legal age * Do not present pain when walking more than 2/10 * Be able to walk with or without technical aids for a period of 6 minutes (as per patient's statement)

Exclusion criteria

* Suffer from heart problems * Bone metastases at risk of fracture * Osteoporosis at high risk of fracture * Unbalanced Hypertension (hypertension) * Not being able to carry out the walk tests in their entirety * Not being able to perform the gait tests for reasons related to the side effects of the treatments (anemia, undernutrition, vomiting, severe fatigue, risk of thrombocytopenia, pain). * Not being able to carry out the walking test because of a lack of understanding of the instructions or because of psychological problems.

Design outcomes

Primary

MeasureTime frameDescription
Primary endpoint: feasibility of the 2MWT and the 10MeWTthrough study completion, an average of 1 yearThe feasibility of the different tests will be assessed in an oncological setting.
Primary endpoint: criterion validity with the 6MWTthrough study completion, an average of 1 yearCriterion validity will be assessed by calculating the strength of the correlation between the 2MWT/10MeWT and the 6MWT.

Secondary

MeasureTime frameDescription
Secondary endpoint: convergent construct validitythrough study completion, an average of 1 yearConvergent construct validity will be evaluated by calculating the strength of the correlation between the 2MWT and the 10m walk test at comfortable/fast speed
Secondary endpoint: criterion validity between 10m walk test and 10m walk test self-testedthrough study completion, an average of 1 yearCriterion validity will be assessed by calculating the strength of the correlation between the 10m walk test self-tested and the 10m walk test timed by the examiner.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026